Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Fellowes

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Pathology|February 14, 2022
Tumour mutational burden: an overview for pathologistsKenneth D Doig, Andrew Fellowes, Prudence Scott, et al.
Translational Lung Cancer Research|April 15, 2015
Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyondChristine Khoo, Toni-Maree Rogers, Andrew Fellowes, et al.
Methods in Molecular Biology (Clifton, N.J.)|May 30, 2014
Studying cancer genomics through next-generation DNA sequencing and bioinformaticsMaria A Doyle, Jason Li, Ken Doig, et al.
Lung Cancer (Amsterdam, Netherlands)|June 19, 2016
Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencingBrett Doble, Thomas John, David Thomas, et al.
BMJ Open|April 22, 2014
Key health outcomes for children and young people with neurodisability: qualitative research with young people and parentsAmanda Allard, Andrew Fellowes, Valerie Shilling, et al.
Haematologica|May 20, 2014
A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapyDiane M T Hanna, Andrew Fellowes, Ravikiran Vedururu, et al.
Digestive Diseases and Sciences|October 1, 2013
Characterization of a novel tumorigenic esophageal adenocarcinoma cell line: OANC1Nicholas J Clemons, Hongdo Do, Christina Fennell, et al.
Pathology|February 18, 2022
SMARCB1/INI1-deficient primary lung carcinoma with hepatic metastasisJames A Rickard, Marian L Burr, Bernadette Williams, et al.
Pathology|May 10, 2021
EGFR mutation profile in Australian patients with non-small cell lung cancerScott Mead, Mark Lucas, Jia-Min Pang, et al.
Annals of Hematology|February 6, 2017
Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratoryRishu Agarwal, Piers Blombery, Michelle McBean, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Pathology|February 14, 2022
Tumour mutational burden: an overview for pathologistsKenneth D Doig, Andrew Fellowes, Prudence Scott, et al.
Translational Lung Cancer Research|April 15, 2015
Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyondChristine Khoo, Toni-Maree Rogers, Andrew Fellowes, et al.
Methods in Molecular Biology (Clifton, N.J.)|May 30, 2014
Studying cancer genomics through next-generation DNA sequencing and bioinformaticsMaria A Doyle, Jason Li, Ken Doig, et al.
Lung Cancer (Amsterdam, Netherlands)|June 19, 2016
Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencingBrett Doble, Thomas John, David Thomas, et al.
BMJ Open|April 22, 2014
Key health outcomes for children and young people with neurodisability: qualitative research with young people and parentsAmanda Allard, Andrew Fellowes, Valerie Shilling, et al.
Haematologica|May 20, 2014
A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapyDiane M T Hanna, Andrew Fellowes, Ravikiran Vedururu, et al.
Digestive Diseases and Sciences|October 1, 2013
Characterization of a novel tumorigenic esophageal adenocarcinoma cell line: OANC1Nicholas J Clemons, Hongdo Do, Christina Fennell, et al.
Pathology|February 18, 2022
SMARCB1/INI1-deficient primary lung carcinoma with hepatic metastasisJames A Rickard, Marian L Burr, Bernadette Williams, et al.
Pathology|May 10, 2021
EGFR mutation profile in Australian patients with non-small cell lung cancerScott Mead, Mark Lucas, Jia-Min Pang, et al.
Annals of Hematology|February 6, 2017
Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratoryRishu Agarwal, Piers Blombery, Michelle McBean, et al.
Pageof 5